

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Jiangsu Recbio Technology Co., Ltd.**

**江蘇瑞科生物技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2179)**

## **VOLUNTARY ANNOUNCEMENT**

### **COMPLETION OF SUBJECT ENROLLMENT AND VACCINATION FOR THE COMPARATIVE STUDY BETWEEN ReCOV AND mRNA VACCINES**

This announcement is made by Jiangsu Recbio Technology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on voluntary basis. Reference is made to the voluntary announcement dated August 3, 2022 made by the Company in relation to, among others, the approval of the comparative study between ReCOV and mRNA vaccines by the Food and Drug Administration (“**FDA**”) of the Philippines.

The board of directors of the Company (the “**Board**”) is pleased to announce that, the Company has completed the subject enrollment and dosing for the comparative phase II clinical trial between its recombinant protein COVID-19 vaccine, ReCOV (“**ReCOV**”) and Pfizer’s mRNA vaccine COMIRNATY®. It has only taken around two weeks from the receipt of clinical trial approval to completion of the subject enrollment and dosing, which clearly demonstrates the high efficiency and execution capability of the clinical team of the Group.

A total of 600 subjects have been enrolled in this phase II clinical trial. After completion of the booster vaccination, safety and immunogenicity follow-up will be conducted on all the subjects.

ReCOV is a recombinant COVID-19 vaccine being developed by the Company with its technology platforms including the novel adjuvant and protein engineering platforms, and the adjuvant used therein is the self-developed novel adjuvant BFA03. Based on the relevant studies conducted by the Company, ReCOV can induce high titers of neutralizing antibody and Th1 biased cellular immune response, and has shown favourable neutralizing effect and immune persistence against variants including Omicron variant and Delta variant. It has a variety of comprehensive advantages, including overall positive safety profile, potential growth in production scale, low production cost, preparation stability, and ability to be stored and transported at room temperature.

**Shareholders and potential investors should note that the Group may not develop or market ReCOV successfully and should exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Jiangsu Recbio Technology Co., Ltd.**  
**Dr. Liu Yong**  
*Chairman*

Jiangsu Province, the PRC, August 19, 2022

*As at the date of this announcement, the Board comprises Dr. Liu Yong as the chairman of the Board and an executive Director, Dr. Chen Jianping and Mr. Li Bu as executive Directors, Dr. Hong Kunxue, Dr. Zhou Hongbin, Mr. Zhao Hui, Dr. Du Wei and Dr. Feng Tao as non-executive Directors, and Mr. Liang Guodong, Dr. Xia Lijun, Professor Gao Feng and Professor Yuen Ming Fai as independent non-executive Directors.*